FTSE MIB
33.629,21 -107,19 (-0,32%) Dow Jones
38.667,53 +441,87 (+1,16%) Nasdaq
16.143,32 +302,36 (+1,91%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
78,34 -0,61 (-0,77%) Bitcoin EUR
57.584,39 +2.651,00 (+4,83%)
Lyell Immunopharma, Inc. (LYEL)
- GlobeNewswire
Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Presentations to highlight new nonclinical data on product candidates, new technologies, innovations designed to shorten TIL manufacturing and clinical trials in progressSOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announced today that six abstracts highlighting its broad pipeline of clinical and preclinical produ
- GlobeNewswire
Lyell Immunopharma to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the following upcoming healthcare conferences: Morgan Stanley 21st Annual Global Healthcare Conference Monday, September 11, 4:55 p.m. ET H.C. Wainwright 25th Annual Global Investment Conferen
- GlobeNewswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023
Cash, cash equivalents and marketable securities of $632.7 million as of June 30, 2023 support advancing multiple product candidates through key clinical milestonesRemain on track for initial clinical data from two lead product candidates in 2024Further strengthened executive leadership with appointment of Matt Lang, J.D., as Chief Business Officer SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company
